Jazz received US approval of Ziihera as a first-line treatment of all HER2-positive advanced gastroesophageal adenocarcinoma, or GEA, used in addition to chemotherapy, with or without Tevimbra. Additional phase 3 data further reinforced its survival advantage over Herceptin with longer follow-up.
The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.
Jazz will face branded competition from Wakix and Lumryz, in addition to generic pressure, which will likely erode Jazz's patient share.
|
Metric
|
JAZZ
|
GMAB
|
IONS
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.54 | 21.72 | — |
Price/Book Value | 3.14 | 3.64 | 16.57 |
Price/Sales | 3.26 | 5.45 | 8.21 |
Price/Cash Flow | 8.77 | 22.16 | — |
|
Metric
|
JAZZ
|
GMAB
|
IONS
|
|---|---|---|---|
Quick Ratio | 1.38 | 2.44 | 6.70 |
Current Ratio | 1.78 | 2.46 | 7.89 |
Interest Coverage | 5.26 | 3.88 | −5.82 |
|
Metric
|
JAZZ
|
GMAB
|
IONS
|
|---|---|---|---|
Return on Assets (Normalized) | 16.01% | 11.74% | −12.57% |
Return on Equity (Normalized) | 42.74% | 21.07% | −75.28% |
Return on Invested Capital (Normalized) | 20.79% | 14.75% | −14.91% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>p?y&Qn | LOCK|?bC& | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@>r&y&Q | LOCK|#QWv | $76B | |||
| Moderna Inc
MRNA
| LOCK|FY#WK<p | LOCK|r%L | $75B | |||
| argenx SE ADR
ARGX
| LOCK|p>wR#$ | LOCK|J^b | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|rwMG?Zv | LOCK|X> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|X&zbsg$ | LOCK|XPnW | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|N%YtT>b | LOCK|<sN% | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|vTgq$W< | LOCK|@& | $24B | |||
| Incyte Corp
INCY
| LOCK|?vV^kS | LOCK|D^ | $24B |
United States